Here, the goal of our study is to address our hypothesis that combination therapy employing two brain penetrant agents adagrasib and abemaciclib will have intracranial efficacy in preclinical xenograft models of NSCLC BM genetically defined by the co-occurrence of KRAS-G12C and CDKN2A homozygous deletion. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.